Evidence map›Paper›PMID 34648050›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2022

Disease-free time stratification in locally recurrent head and neck carcinoma after definitive radiotherapy or chemoradiotherapy.

Philippe Gorphe, Antoine Moya-Plana, Joanne Guerlain, Yungan Tao, France Nguyen, Ingrid Breuskin, Pierre Blanchard, Stéphane Temam

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Philippe GorpheDepartment of Head and Neck Oncology, Gustave Roussy Institute, University Paris-Saclay, 114 Rue Edouard Vaillant, 94800, Villejuif, France. philippe.gorphe@gustaveroussy.fr.ORCID http://orcid.org/0000-0001-7604-4964
Antoine Moya-PlanaDepartment of Head and Neck Oncology, Gustave Roussy Institute, University Paris-Saclay, 114 Rue Edouard Vaillant, 94800, Villejuif, France.
Joanne GuerlainDepartment of Head and Neck Oncology, Gustave Roussy Institute, University Paris-Saclay, 114 Rue Edouard Vaillant, 94800, Villejuif, France.
Yungan TaoDepartment of Radiotherapy, Gustave Roussy Institute, University Paris-Saclay, Villejuif, France.
France NguyenDepartment of Radiotherapy, Gustave Roussy Institute, University Paris-Saclay, Villejuif, France.
Ingrid BreuskinDepartment of Head and Neck Oncology, Gustave Roussy Institute, University Paris-Saclay, 114 Rue Edouard Vaillant, 94800, Villejuif, France.
Pierre BlanchardDepartment of Radiotherapy, Gustave Roussy Institute, University Paris-Saclay, Villejuif, France.
Stéphane TemamDepartment of Head and Neck Oncology, Gustave Roussy Institute, University Paris-Saclay, 114 Rue Edouard Vaillant, 94800, Villejuif, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThere is no standard definition of disease-free interval before local recurrence after treatment in head and neck carcinoma (HNSCC). We evaluated an easy-to-use stratification and its association with survival in a large cohort of patients.

methodsWe performed a retrospective cohort analysis of prognostic variables in 325 HNSCC patients with a local recurrence after definitive radiotherapy or concurrent chemoradiotherapy. Endpoints were overall survival (OS) and post-recurrence survival (PRS).

resultsVariables associated with the survival were the patient age (OS p < 0.0001, PRS p < 0.0001), the initial disease stage (OS p = 0.24, PRS p = 0.0358), localization (OS p = 0.012, PRS p = 0.0002), a complete initial response to treatment (OS p < 0.0001, PRS p = 0.019), synchronous regional or distant metastatic disease (OS p = 0.0094, PRS p < 0.0001), a salvage surgery (OS p < 0.0001, PRS p < 0.0001) and time to recurrence (OS p = 0.0002, PRS p = 0.0029). Time to recurrence could be stratified between specific prognostic time categories that comprised disease persistence, early recurrence (< 12 months), standard recurrence (12 months-5 years) and late recurrence (> 5 years).

conclusionIn HNSCC patients, time to local recurrence is a prognostic variable that can be defined using an easy-to-use stratification.

Indexed as

Head and Neck NeoplasmsNeoplasm Recurrence, LocalChemoradiotherapyHumansPrognosisRetrospective StudiesSquamous Cell Carcinoma of Head and NeckHead and neck neoplasmsNeoplasm recurrence, localNeoplasms, residualNeoplasms, second primary

Identifiers

PMID34648050

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.